Showing posts sorted by relevance for query BIOPHAGES. Sort by date Show all posts
Showing posts sorted by relevance for query BIOPHAGES. Sort by date Show all posts

Tuesday, June 08, 2021

#BIOPHAGES

Trained viruses prove more effective at fighting antibiotic resistance

Practice boosts phage potency in evolutionary battleground with deadly bacteria

UNIVERSITY OF CALIFORNIA - SAN DIEGO

Research News

The threat of antibiotic resistance rises as bacteria continue to evolve to foil even the most powerful modern drug treatments. By 2050, antibiotic resistant-bacteria threaten to claim more than 10 million lives as existing therapies prove ineffective.

Bacteriophage, or "phage," have become a new source of hope against growing antibiotic resistance. Ignored for decades by western science, phages have become the subject of increasing research attention due to their capability to infect and kill bacterial threats.

A new project led by University of California San Diego Biological Sciences graduate student Joshua Borin, a member of Associate Professor Justin Meyer's laboratory, has provided evidence that phages that undergo special evolutionary training increase their capacity to subdue bacteria. Like a boxer in training ahead of a title bout, pre-trained phages demonstrated they could delay the onset of bacterial resistance.

The study, which included contributions from researchers at the University of Haifa in Israel and the University of Texas at Austin, is published June 8 in the Proceedings of the National Academy of Sciences.

"Antibiotic resistance is inherently an evolutionary problem, so this paper describes a possible new solution as we run out of antibiotic drug options," said Borin. "Using bacterial viruses that can adapt and evolve to the host bacteria that we want them to infect and kill is an old idea that is being revived. It's the idea of the enemy of our enemy is our friend."

The idea of using phages to combat bacterial infections goes back to the days prior to World War II. But as antibiotic drugs became the leading treatment for bacterial infections, phage research for therapeutic potential was largely forgotten. That mindset has changed in recent years as deadly bacteria continue to evolve to render many modern drugs ineffective.

Borin's project was designed to train specialized phage to fight bacteria before they encounter their ultimate bacterial target. The study, conducted in laboratory flasks, demonstrated classic evolutionary and adaptational mechanisms at play. The bacteria, Meyer said, predictably moved to counter the phage attack. The difference was in preparation. Phages trained for 28 days, the study showed, were able to suppress bacteria 1,000 times more effectively and three- to eight-times longer than untrained phage.

"The trained phage had already experienced ways that the bacteria would try to dodge it," said Meyer. "It had 'learned' in a genetic sense. It had already evolved mutations to help it counteract those moves that the bacteria were taking. We are using phage's own improvement algorithm, evolution by natural selection, to regain its therapeutic potential and solve the problem of bacteria evolving resistance to yet another therapy."

The researchers are now extending their findings to research how pre-trained phages perform on bacteria important in clinical settings, such as E. coli. They are also working to evaluate how well training methods work in animal models.

UC San Diego is a leader in phage research and clinical applications. In 2018 the university's School of Medicine established the Center for Innovative Phage Applications and Therapeutics, the first dedicated phage therapy center in North America.

"We have prioritized antibiotics since they were developed and now that they are becoming less and less useful people are looking back to phage to use as therapeutics," said Meyer. "More of us are looking into actually running the experiments necessary to understand the types of procedures and processes that can improve phage therapeutics."

###

The study's full author list includes: Joshua Borin, Sarit Avrani, Jeffrey Barrick, Katherine Petrie and Justin Meyer.



CAPTION

Trained and untrained phages are pitted against bacteria in battleground flasks to evaluate which is more effective at killing.

Tuesday, July 25, 2023

 BIOPHAGES

Treating bladder infections with viruses


Peer-Reviewed Publication

ETH ZURICH

Electron micrograph of phages 

IMAGE: ELECTRON MICROGRAPH OF PHAGES view more 

CREDIT: MATTHEW DUNNE / SCOPEM / ETH ZURICH



About one in two women are affected by cystitis during her lifetime, and many suffer from recurrent urinary tract infections. Bladder infections are not only painful and potentially dangerous, but they also pose a significant dilemma for physicians. With antibiotic resistance becoming widespread in urinary tract infections and continually increasing, physicians are often forced to blindly prescribe antibiotics without knowing their effectiveness against the pathogen causing the infection. This is because it takes several days to identify a specific pathogen using conventional diagnostics.

Researchers at ETH Zurich, in collaboration with Balgrist University Hospital, have now developed a rapid test that employs the natural viral predators of bacteria, bacteriophages. The researchers also genetically modified the phages to make them more efficient at destroying the pathogenic bacteria.

Fast and reliable diagnosis

Phages are highly specialised viruses. Each species of phage infects only one particular type or strain of bacteria. ETH Zurich scientists from the Food Microbiology research group led by Professor Martin Loessner are now taking advantage of this unique characteristic. The first step was to identify the phages that are effective against the three main types of bacteria implicated in urinary tract infections, namely Escherichia coliKlebsiella and Enterococci. These natural phages were then modified in such a way that any bacteria they recognize and infect are propelled to produce an easy-​to-measure light signal.

Using this method, the researchers were able to reliably detect the pathogenic bacteria directly from a urine sample in less than four hours. In the future, the method could make it possible to prescribe a suitable antibiotic immediately after diagnosis and thus minimize resistance development and improve antibiotic stewardship.

The method also has another advantage: it allows physicians to predict which patients are likely to respond particularly well to a tailored phage therapy, as the strength of the light signal produced in the assay already indicates how efficient the phages are in attacking the bacterium – the more the sample glows, the better the bacterium will respond to the therapy.

Double-​action sniper

Phage therapies have been used for over 100 years but fell into oblivion in Western industrialised countries with the discovery of penicillin. In view of increasing antibiotic resistance, they are currently seeing a renaissance. They also have the decisive advantage of attacking only a single target bacterium, much like a sniper.

However, previous therapeutic approaches have one problem: “Phages aren’t interested in completely killing their host, the pathogenic bacterium,” explains ETH researcher Samuel Kilcher, one of the study’s two final authors. To enhance the phages’ effectiveness, the researchers genetically modified them. The modified phages produce not only new phages inside the infected host bacterium, but also bacteriocins. Once they are released, these bacteria-​killing proteins are particularly effective against bacterial strains that have altered parts of their surface in such a way that the phages no longer recognise them. This double-​barrelled attack makes the treatment more effective.

From the laboratory to the clinic

In individual cases, such as the recent rescue of a lung patient at the University Hospital of Geneva, phage therapies have been successfully used experimentally. “There are also many academic and commercial clinical trials underway worldwide that are systematically investigating the potential of natural and genetically optimized phages,” says Matthew Dunne, one of the study's final authors. However, there is a long way to go before such therapies can be applied more widely in Western countries. In addition to extensive clinical studies, regulatory adjustments would also be useful, taking into account the fact that phages are biological entities that co-​evolve with their bacterial hosts, i.e., they are constantly evolving.

The present study is a proof of concept. Next, the ETH Zurich researchers, together with their partners from Balgrist University Hospital, will test the efficacy of the new phage therapy in a clinical trial with selected patients.

Wednesday, March 06, 2024

 

Dr. Schooley's call to action: Elevating phage therapy trials through strategic translational research


Meeting Announcement

MITOCHONDRIA-MICROBIOTA TASK FORCE

Prof. Robert T. Schooley will present a keynote speech during Targeting Phage Therapy 2024 

IMAGE: 

IN HIS TALK AT TARGETING PHAGE THERAPY 2024, PROF. SCHOOLEY WILL DISCUSS CRITICAL STRATEGIES FOR INTEGRATING TRANSLATIONAL RESEARCH INTO CLINICAL TRIALS IN PHAGE THERAPY, ENSURING THEIR SUCCESS AND IMPACT.
 

view more 

CREDIT: TARGETING PHAGE THERAPY 2024



The 7th World Conference on Targeting Phage Therapy is being organized on June 20-21, 2024 at Corinthia Palace Malta.

Robert T. Schooley, M.D., Professor of Medicine at the University of California, San Diego, and Co-Director of the Center for Innovative Phage Applications and Therapeutics and member of the Executive Committee for the University of California Disaster Resilience Network, will introduce Phage Therapy 2024 with a key note talk titled "Phage Therapeutics 2024: Essential Translational Research Components for Clinical Trials.

Dr. Schooley will highlight the pivotal moment that phage therapy research finds itself in. With Phase 2 studies transitioning to Phase 3 trials, he stresses the critical need for a unified approach in integrating translational research components into clinical trials to ensure their success and meaningfulness.

Dr. Schooley critiques the current trend in trial design, which often aims narrowly at achieving clinical endpoints for regulatory approval, yet lacks the depth to provide insights or guidance should the trial not meet its objectives.

He references the instructive case of one study, which, despite its failure, offered valuable lessons due to its comprehensive assessment approach. This study revealed significant insights post hoc, such as issues with microbiology, phage-phage antagonism, and dilution effects, which were not addressed upfront. These revelations underscore the necessity of including detailed evaluations in clinical trials to verify that phages reach the infection site in effective quantities and intervals, to monitor the development of resistance during the study, and to assess the impact of phage-specific antibodies on treatment efficacy.

Dr. Schooley's message is a call to action for the phage therapy research community to adopt a more thorough and insightful approach in clinical trials. This includes the implementation of substudies to document key aspects of phage therapy application and the development of consensus protocols for evaluating phage-specific immunity, pharmacokinetics/pharmacodynamics (PK/PD) relationships, and phage resistance mechanisms. Such measures are vital for understanding why certain therapeutic interventions succeed or fail, enabling researchers to refine and improve treatment strategies.

In advocating for this approach, Dr. Schooley highlights a fundamental challenge: the repetition of past mistakes due to a lack of comprehensive analysis and learning from failed trials. Without addressing this issue, the field risks stagnation, unable to leverage cumulative experience to accelerate progress. His passionate plea underscores the importance of not just aiming for short-term successes in phage therapy research but also building a robust and insightful framework that enhances the field's overall efficacy and resilience.

To learn more about Targeting Phage Therapy 2024 program and speakers, please visit: www.phagetherapy-site.com 


SEE

https://plawiuk.blogspot.com/search?q=PHAGES


Thursday, May 09, 2019

BIOPHAGE AKA BACTERIOPHAGES
"We were at the point where there was no other hope, they said she wasn't going to leave the hospital and had less than 1% chance of survival."
But after being treated with a cocktail of bacteriophages – viruses which are specialised to kill the bacteria but not infect human cells – she is now back taking her GCSEs and learning to drive. 

DISCOVERED BY RUSSIANS AND DEVELOPED BY SOVIET SCIENCE AS AN ALTERNATIVE THERAPY TO ANTIBIOTICS, IGNORED BY THE WEST FOR SEVENTY YEARS UNTIL THE ADVENT OF SUPERBUGS

Related image
bacteriophage also known informally as a phage is a virus that infects and replicates within bacteria and archaea. The term was derived from "bacteria" and...
Phage therapy or viral phage therapy is the therapeutic use of bacteriophages to treat pathogenic bacterial infections. Phage therapy has many potential ...


May 30, 2006 - Bacteriophages are viruses found virtually everywhere—from soil to ... Western scientists, and patients, to travel to former Soviet Georgia to give 
by D Myelnikov - ‎2018 - ‎Cited by 4 - ‎Related articles
Oct 12, 2018 - To a historian of biologybacteriophages are most familiar as a key model ... Why did phage therapy appeal to Soviet medicine, and why did it ...


Bacteriophage Therapy | Antimicrobial Agents and Chemotherapy

https://aac.asm.org/content/45/3/649





INDEPENDENT.CO.UK
'We were at the point where there was no other hope, they said she wasn't going to leave the hospital and had less than 1 per cent chance of survival'

Isabelle was told she had less than a 1% chance of survival after a bacterial infection ravaged her body.